**Supplementary File 1A. Area under the ROC curve analyses for the various testing methods depending on the variable selection protocol using data without batch adjustment.** Similar to the batch-adjusted data, the neural network using the fold change variable outperformed the other methods in terms of classifier accuracy and did not overfit the predictions to the training set.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Training set (N=135) | | | Testing set (N=44) | | |
|  | Variable selection | | | Variable selection | | |
| Method | Significance-based | CFS subset | Fold change | Significance-based | CFS subset | Fold change |
| LDA | 0.81 (0.74-0.88) | 0.76 (0.68-0.84) | 0.73 (0.65-0.82) | 0.78 (0.65-0.92) | 0.75 (0.60-0.89) | 0.74 (0.59-0.88) |
| LR | 0.82 (0.75-0.89) | 0.76 (0.68-0.84) | 0.74 (0.65-0.82) | 0.81 (0.68-0.94) | 0.75 (0.60-0.89) | 0.78 (0.64-0.92) |
| NN | 0.89 (0.84-0.95) | 0.80 (0.73-0.88) | 0.93 (0.89-0.98) | 0.77 (0.63-0.91) | 0.71 (0.56-0.86) | 0.90 (0.80-0.99) |
| SVM | 0.82 (0.75-0.89) | 0.66 (0.57-0.75) | 0.87 (0.81-0.93) | 0.74 (0.60-0.89) | 0.66 (0.50-0.82) | 0.74 (0.60-0.89) |
| MARS | 0.87 (0.81-0.93) | 0.84 (0.77-0.91) | 0.79 (0.71-0.86) | 0.56 (0.39-0.73) | 0.69 (0.54-0.85) | 0.67 (0.51-0.83) |
| Bayes | 0.81 (0.73-0.88) | 0.80 (0.73-0.87) | 0.80 (0.73-0.87) | 0.74 (0.60-0.89) | 0.64 (0.48-0.81) | 0.72 (0.57-0.87) |
| LADtree | 0.97 (0.94-1.00) | 0.96 (0.92-0.99) | 0.96 (0.92-0.99) | 0.64 (0.48-0.81) | 0.67 (0.51-0.83) | 0.59 (0.42-0.76) |
| FT | 0.81 (0.74-0.89) | 0.75 (0.66-0.83) | 0.83 (0.77-0.90) | 0.81 (0.68-0.94) | 0.60 (0.44-0.77) | 0.82 (0.70-0.95) |
| Bayes  Net | 0.80 (0.73-0.88) | 0.80 (0.73-0.88) | 0.80 (0.73-0.88) | 0.65 (0.49-0.81) | 0.65 (0.49-0.81) | 0.65 (0.49-0.81) |
| RF | 1.00 (1.00-1.00) | 1.00 (1.00-1.00) | 1.00 (1.00-1.00) | 0.77 (0.63-0.91) | 0.72 (0.57-0.87) | 0.68 (0.52-0.84) |
| EN | 0.83 (0.76-0.90) | 0.78 (0.70-0.85) | 0.81 (0.74-0.88) | 0.80 (0.67-0.93) | 0.72 (0.57-0.87) | 0.80 (0.66-0.93) |
| LDA - Linear discriminant analysis  LG - Logistic regression  NN – Neural network  SVM - Support vector machine  Bayes – Naive Bayes  MARS - Multivariate adaptive regression splines  FT – Functional tree  Bayes net - Bayesian network  RF – Random forest  EN – Elastic network regression  95% Confidence intervals in parentheses | | | | | | |

**Supplementary File 1B Individual sample predictions of the tested classification models built on the unadjusted fold change-based variable selection miRNA subset.**

| ID | Study | Stage | Grade | Histology | Age | CA-125 | LDA | LR | NN | SVM | Bayes | MARS | LAD Tree | FT | Bayes net | RF | EN | CA-125 >35 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | NECC | \* | \* | control | 53 | ‡ | BBC | CA | BBC | BBC | CA | BBC | BBC | BBC | CA | BBC | BBC | \* |
| 2 | PMP | \* | 0 | serous borderline | 58 | 763 | CA | CA | BBC | CA | CA | BBC | BBC | CA | CA | BBC | CA | CA |
| 3 | PMP | III | 3 | serous adenocarcinoma | 59 | 25.8 | BBC | CA | BBC | CA | CA | BBC | CA | BBC | BBC | CA | BBC | BBC |
| 4 | PMP | IV | 3 | serous adenocarcinoma | 66 | ‡ | CA | CA | CA | CA | BBC | CA | CA | CA | CA | CA | CA | \* |
| 5 | PMP | \* | \* | endometrioma | 49 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 6 | PMP | I | 1 | clear cell adenocarcinoma | 50 | 13 | BBC | CA | CA | CA | BBC | BBC | CA | BBC | CA | CA | BBC | BBC |
| 7 | PMP | \* | \* | serous cystadenoma | 47 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | \* |
| 8 | PMP | I | 2 | endometrioid adenocarcinoma | 49 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| 9 | PMP | III | 3 | clear cell adenocarcinoma | 54 | 87.6 | BBC | BBC | CA | CA | CA | CA | BBC | BBC | BBC | CA | BBC | CA |
| 10 | PMP | \* | \* | serous cystadenoma | 45 | 17.4 | BBC | CA | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC |
| 11 | PMP | \* | 0 | serous borderline | 59 | 42.8 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA |
| 12 | PMP | II | 2 | clear cell adenocarcinoma | 59 | 125 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 13 | PMP | \* | \* | serous cystadenoma | 70 | 12 | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| 14 | PMP | III | 3 | endometrioid adenocarcinoma | 57 | 382.2 | BBC | BBC | CA | CA | CA | CA | CA | BBC | BBC | CA | BBC | CA |
| 15 | PMP | \* | 0 | serous borderline | 56 | 450.3 | BBC | CA | CA | CA | CA | BBC | BBC | CA | CA | BBC | CA | CA |
| 16 | PMP | III | 3 | endometrioid adenocarcinoma | 63 | 1002 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 17 | PMP | \* | 0 | serous borderline | 69 | 388 | BBC | BBC | BBC | CA | CA | CA | CA | BBC | BBC | CA | BBC | CA |
| 18 | PMP | \* | 0 | serous borderline | 50 | 118 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | CA |
| 19 | PMP | III | 2 | endometrioid adenocarcinoma | 55 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| 20 | PMP | II | 3 | serous adenocarcinoma | 74 | 9 | CA | CA | BBC | CA | CA | CA | CA | CA | BBC | CA | CA | BBC |
| 21 | PMP | \* | \* | endometrioma | 65 | 48 | CA | CA | BBC | BBC | CA | CA | CA | BBC | BBC | BBC | CA | CA |
| 22 | PMP | \* | \* | endometrioma | 52 | ‡ | BBC | BBC | CA | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | \* |
| 23 | PMP | \* | 0 | serous borderline | 51 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 24 | PMP | I | 1 | clear cell adenocarcinoma | 64 | 30.5 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | BBC |
| 25 | PMP | \* | 0 | serous borderline | 56 | 9.4 | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| 26 | PMP | III | 3 | serous adenocarcinoma | 55 | 277.2 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 27 | PMP | \* | \* | endometrioma | 55 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 28 | NECC | \* | \* | control | 45 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | CA | CA | CA | CA | BBC | \* |
| 29 | NECC | \* | \* | control | 71 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 30 | PMP | \* | \* | endometrioma | 60 | 10.5 | CA | CA | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | CA | BBC |
| 31 | PMP | \* | \* | serous cystadenoma | 59 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 32 | PMP | II | 3 | serous adenocarcinoma | 63 | 568 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 33 | PMP | III | 3 | serous adenocarcinoma | 48 | 3723 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 34 | NECC | \* | \* | control | 58 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 35 | PMP | \* | \* | serous cystadenoma | 55 | ‡ | CA | BBC | BBC | BBC | CA | CA | BBC | BBC | BBC | CA | CA | \* |
| 36 | PMP | II | 3 | serous adenocarcinoma | 52 | 49 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 37 | PMP | II | 3 | serous adenocarcinoma | 59 | 7000 | CA | CA | CA | CA | BBC | CA | CA | CA | CA | CA | CA | CA |
| 38 | NECC | \* | \* | control | 60 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 39 | PMP | III | 3 | serous adenocarcinoma | 49 | ‡ | BBC | CA | CA | CA | BBC | CA | CA | CA | CA | CA | CA | \* |
| 40 | PMP | \* | \* | endometrioma | 56 | 70 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA |
| 41 | PMP | II | 2 | endometrioid adenocarcinoma | 52 | 1889 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 42 | NECC | \* | \* | control | 59 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 43 | PMP | II | 3 | serous adenocarcinoma | 69 | 213 | CA | CA | CA | CA | BBC | CA | CA | CA | CA | CA | CA | CA |
| 44 | PMP | \* | \* | endometrioma | 50 | 5 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| 45 | PMP | I | 1 | endometrioid adenocarcinoma | 57 | 23 | CA | CA | CA | CA | BBC | CA | CA | CA | CA | CA | CA | BBC |
| 46 | NECC | \* | \* | control | 52 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 47 | PMP | \* | \* | endometrioma | 53 | 336 | BBC | CA | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | CA |
| 48 | PMP | II | 3 | serous adenocarcinoma | 58 | 268 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 49 | PMP | \* | \* | endometrioma | 56 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | \* |
| 50 | PMP | I | 2 | endometrioid adenocarcinoma | 66 | 31.2 | BBC | BBC | BBC | BBC | BBC | CA | BBC | CA | BBC | CA | BBC | BBC |
| 51 | PMP | \* | 1 | endometrioid adenocarcinoma | 62 | 1726 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 52 | NECC | \* | \* | control | 63 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 53 | PMP | \* | 0 | serous borderline | 54 | 4.9 | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | CA | CA | BBC | BBC |
| 54 | PMP | II | 3 | serous adenocarcinoma | 59 | 107.9 | CA | CA | CA | CA | BBC | CA | CA | CA | CA | CA | CA | CA |
| 55 | PMP | II | 3 | serous adenocarcinoma | 60 | 23.1 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC |
| 57 | PMP | I | 2 | endometrioid adenocarcinoma | 59 | ‡ | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 58 | PMP | \* | 0 | serous borderline | 69 | ‡ | CA | CA | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 59 | PMP | I | 3 | serous adenocarcinoma | 61 | 302.6 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 60 | PMP | III | 3 | endometrioid adenocarcinoma | 56 | 58 | CA | CA | CA | CA | BBC | CA | CA | CA | CA | CA | CA | CA |
| 61 | PMP | \* | \* | endometrioma | 55 | 172.4 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA |
| 62 | PMP | I | 2 | endometrioid adenocarcinoma | 68 | ‡ | CA | CA | CA | CA | BBC | CA | CA | BBC | CA | CA | BBC | \* |
| 63 | PMP | II | 3 | serous adenocarcinoma | 52 | 367.3 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 64 | PMP | \* | 0 | serous borderline | 45 | 16.5 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| 65 | PMP | I | 1 | serous adenocarcinoma | 60 | ‡ | BBC | BBC | CA | CA | BBC | BBC | CA | BBC | BBC | CA | BBC | \* |
| 66 | PMP | III | 3 | serous adenocarcinoma | 51 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| 67 | PMP | I | 3 | serous adenocarcinoma | 56 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | CA | BBC | \* |
| 68 | PMP | \* | 0 | serous borderline | 49 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 69 | PMP | III | 3 | serous adenocarcinoma | 70 | 1212 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 70 | PMP | I | 1 | clear cell adenocarcinoma | 51 | ‡ | CA | CA | CA | CA | BBC | BBC | CA | CA | CA | CA | CA | \* |
| 71 | PMP | I | 2 | endometrioid adenocarcinoma | 57 | 209.2 | CA | CA | CA | CA | CA | CA | CA | BBC | BBC | CA | BBC | CA |
| 72 | PMP | \* | 0 | serous borderline | 52 | 42 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA |
| 73 | PMP | I | 3 | serous adenocarcinoma | 52 | 38.9 | CA | CA | CA | CA | CA | CA | CA | CA | BBC | CA | CA | CA |
| 74 | PMP | I | 1 | endometrioid adenocarcinoma | 71 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | \* |
| 75 | PMP | \* | \* | serous cystadenoma | 56 | ‡ | BBC | CA | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | \* |
| 76 | NECC | \* | \* | control | 45 | ‡ | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | CA | \* |
| 77 | PMP | \* | \* | serous cystadenoma | 69 | ‡ | BBC | BBC | CA | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | \* |
| 78 | NECC | \* | \* | control | 47 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | CA | CA | BBC | \* |
| 79 | PMP | \* | \* | serous cystadenoma | 51 | 87.2 | CA | CA | BBC | CA | BBC | BBC | BBC | BBC | BBC | BBC | CA | CA |
| 80 | PMP | III | 3 | serous adenocarcinoma | 59 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| 81 | PMP | \* | \* | endometrioma | 54 | 20.4 | BBC | BBC | BBC | BBC | CA | CA | CA | BBC | BBC | CA | BBC | BBC |
| 82 | PMP | \* | 0 | serous borderline | 60 | 6.2 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| 83 | NECC | \* | \* | control | 49 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 84 | NECC | \* | \* | control | 48 | ‡ | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 85 | PMP | \* | \* | serous cystadenoma | 55 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| 86 | PMP | I | 3 | serous adenocarcinoma | 53 | 124 | BBC | BBC | CA | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | CA |
| 87 | PMP | \* | \* | serous cystadenoma | 71 | ‡ | CA | CA | BBC | CA | CA | BBC | CA | BBC | CA | BBC | CA | \* |
| 88 | PMP | I | 1 | endometrioid adenocarcinoma | 65 | 25 | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | CA | CA | BBC |
| 89 | PMP | \* | \* | endometrioma | 52 | ‡ | CA | CA | BBC | BBC | CA | BBC | BBC | BBC | CA | BBC | CA | \* |
| 90 | PMP | \* | \* | endometrioma | 56 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 91 | NECC | \* | \* | control | 52 | ‡ | CA | CA | CA | CA | CA | BBC | BBC | CA | CA | BBC | CA | \* |
| 92 | PMP | III | 3 | serous adenocarcinoma | 50 | 7005 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 93 | PMP | I | 1 | endometrioid adenocarcinoma | 47 | 25.6 | BBC | BBC | CA | CA | BBC | BBC | CA | CA | CA | CA | CA | BBC |
| 94 | PMP | II | 3 | endometrioid adenocarcinoma | 56 | 129 | CA | CA | CA | CA | BBC | CA | CA | CA | CA | CA | CA | CA |
| 95 | PMP | III | 3 | serous adenocarcinoma | 60 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| 96 | PMP | \* | \* | endometrioma | 70 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 97 | PMP | III | 2 | endometrioid adenocarcinoma | 51 | 3257 | CA | CA | CA | CA | CA | CA | CA | CA | BBC | CA | CA | CA |
| 98 | NECC | \* | \* | control | 67 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | \* |
| 99 | PMP | I | 3 | endometrioid adenocarcinoma | 56 | 35.2 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 100 | PMP | II | 3 | serous adenocarcinoma | 52 | 1132 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 101 | PMP | II | 3 | mixed with clear cell adenocarcinoma or endometroid component | 59 | 542.6 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 102 | PMP | \* | \* | serous cystadenoma | 53 | ‡ | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 103 | NECC | \* | \* | control | 53 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | \* |
| 104 | PMP | III | 2 | clear cell adenocarcinoma | 62 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| 105 | PMP | I | 1 | endometrioid adenocarcinoma | 45 | 31.4 | BBC | BBC | BBC | CA | BBC | CA | CA | CA | CA | CA | BBC | BBC |
| 106 | PMP | II | 3 | serous adenocarcinoma | 48 | 681 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 107 | PMP | II | 2 | serous adenocarcinoma | 55 | 88.6 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 108 | PMP | III | 3 | clear cell adenocarcinoma | 50 | 721.1 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 109 | PMP | \* | \* | serous cystadenoma | 50 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | \* |
| 110 | PMP | \* | \* | serous cystadenoma | 52 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | CA | \* |
| 111 | PMP | \* | \* | serous cystadenoma | 49 | ‡ | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 112 | PMP | III | 3 | mixed with clear cell adenocarcinoma or endometroid component | 57 | 20.9 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | BBC |
| 113 | PMP | I | 1 | endometrioid adenocarcinoma | 65 | ‡ | BBC | BBC | CA | CA | CA | BBC | CA | CA | CA | CA | CA | \* |
| 114 | PMP | II | 3 | serous adenocarcinoma | 45 | 19.4 | CA | CA | CA | CA | CA | CA | BBC | CA | BBC | BBC | CA | BBC |
| 115 | PMP | I | 2 | serous adenocarcinoma | 52 | ‡ | CA | CA | CA | CA | BBC | BBC | CA | CA | BBC | CA | CA | \* |
| 116 | PMP | I | 1 | serous adenocarcinoma | 73 | 128 | BBC | CA | BBC | BBC | BBC | BBC | CA | BBC | CA | CA | BBC | CA |
| 117 | PMP | \* | 0 | serous borderline | 62 | 42 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | CA |
| 118 | PMP | \* | 0 | serous borderline | 61 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | \* |
| 119 | PMP | II | 3 | endometrioid adenocarcinoma | 46 | 371 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| 120 | PMP | \* | \* | endometrioma | 55 | 4.2 | BBC | BBC | BBC | CA | CA | CA | CA | CA | CA | CA | CA | BBC |
| e1001 | ERA | II | 2 | endometrioid adenocarcinoma | 59 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| e1002 | ERA | III | 3 | serous adenocarcinoma | 70 | 2589 | BBC | BBC | CA | CA | BBC | CA | CA | CA | BBC | CA | BBC | CA |
| e1003 | ERA | II | 1 | endometrioid adenocarcinoma | 70 | 484 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1004 | ERA | III | 3 | serous adenocarcinoma | 59 | 3011 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1005 | ERA | II | 3 | serous adenocarcinoma | 56 | 302.6 | CA | CA | CA | CA | CA | CA | BBC | CA | CA | CA | CA | CA |
| e1006 | ERA | \* | \* | fibrothecoma | 52 | 45 | BBC | CA | CA | CA | CA | CA | CA | BBC | CA | BBC | CA | CA |
| e1007 | ERA | III | 3 | serous adenocarcinoma | 75 | 132 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1008 | ERA | I | 3 | serous adenocarcinoma | 66 | 135 | CA | CA | CA | CA | CA | CA | CA | CA | BBC | CA | CA | CA |
| e1009 | ERA | IV | 3 | serous adenocarcinoma | 55 | 2974.8 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1010 | ERA | \* | \* | simple Cyst | 51 | 795.6 | CA | CA | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | CA |
| e1011 | ERA | III | 3 | serous adenocarcinoma | 66 | 152.7 | BBC | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1012 | ERA | III | 0 | serous borderline | 61 | 274 | CA | CA | BBC | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1013 | ERA | I | 0 | mucinous borderline | 48 | 10.7 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| e1014 | ERA | IV | 3 | serous adenocarcinoma | 59 | 252.3 | CA | CA | CA | CA | CA | CA | CA | CA | BBC | CA | CA | CA |
| e1015 | ERA | III | 3 | serous adenocarcinoma | 59 | 300 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1016 | ERA | II | 3 | clear cell adenocarcinoma | 51 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| e1017 | ERA | II | 3 | serous adenocarcinoma | 61 | 32.6 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | BBC |
| e1019 | ERA | III | 3 | serous adenocarcinoma | 71 | ‡ | CA | CA | CA | CA | CA | CA | CA | CA | BBC | CA | CA | \* |
| e1020 | ERA | III | 3 | serous adenocarcinoma | 73 | ‡ | BBC | BBC | CA | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC | \* |
| e1021 | ERA | IV | 3 | serous adenocarcinoma | 49 | 225.9 | CA | CA | CA | CA | BBC | BBC | CA | BBC | BBC | CA | CA | CA |
| e1022 | ERA | II | 3 | serous adenocarcinoma | 65 | 442 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1023 | ERA | I | 1 | endometrioid adenocarcinoma | 65 | 416.2 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | CA |
| e1024 | ERA | III | 1 | serous adenocarcinoma | 46 | 464 | BBC | BBC | CA | CA | CA | CA | CA | BBC | BBC | CA | BBC | CA |
| e1026 | ERA | III | 3 | metastatic uterine myxoid leiomyosarcoma | 48 | 54.2 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1027 | ERA | III | 0 | serous borderline | 45 | 377 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA |
| e1029 | ERA | \* | \* | adenofibroma | 28 | 12.3 | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | BBC |
| e1030 | ERA | IV | 3 | metastatic uterine papillary serous carcinoma | 68 | 482.9 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1031 | ERA | III | 3 | serous adenocarcinoma | 64 | 278 | CA | BBC | CA | CA | BBC | BBC | BBC | BBC | BBC | BBC | CA | CA |
| e1032 | ERA | III | 3 | serous adenocarcinoma | 56 | 1369 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1033 | ERA | IV | 3 | metastatic uterine epithelioid leiomyosarcoma | 66 | 16.8 | CA | CA | BBC | CA | CA | CA | CA | CA | BBC | CA | CA | BBC |
| e1034 | ERA | IV | 2 | metastatic endometrioid endometrial adenocarcinoma | 49 | 30.5 | BBC | BBC | CA | BBC | BBC | BBC | CA | BBC | BBC | CA | BBC | BBC |
| e1035 | ERA | II | 3 | serous adenocarcinoma | 59 | 40.4 | BBC | BBC | CA | CA | BBC | CA | CA | CA | BBC | CA | BBC | CA |
| e1036 | ERA | \* | \* | serous cystadenoma | 50 | 7.5 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| e1037 | ERA | I | 0 | mucinous borderline | 54 | 49.8 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | CA |
| e1038 | ERA | \* | \* | serous cystadenofibroma | 72 | 21 | CA | CA | BBC | BBC | CA | CA | CA | BBC | CA | CA | CA | BBC |
| e1039 | ERA | \* | \* | serous cystadenoma | 55 | ‡ | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | \* |
| e1040 | ERA | \* | \* | benign Brenner tumor | 44 | 6 | BBC | BBC | CA | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC |
| e1041 | ERA | III | 3 | serous adenocarcinoma | 78 | 92 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1042 | ERA | \* | \* | serous cystadenofibroma | 52 | 16.1 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| e1043 | ERA | \* | \* | serous cystadenofibroma | 55 | 87.2 | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | CA |
| e1044 | ERA | III | 3 | serous adenocarcinoma | 62 | 200.5 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1045 | ERA | III | 3 | serous adenocarcinoma | 69 | 326 | CA | CA | CA | CA | BBC | CA | CA | CA | CA | CA | CA | CA |
| e1046 | ERA | I | 0 | serous borderline | 53 | 172.7 | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | CA |
| e1047 | ERA | III | 3 | serous adenocarcinoma | 68 | ‡ | CA | BBC | CA | CA | CA | CA | CA | CA | CA | CA | CA | \* |
| e1048 | ERA | III | 0 | serous borderline | 53 | 133 | BBC | BBC | CA | CA | BBC | CA | BBC | CA | BBC | CA | BBC | CA |
| e1049 | ERA | II | 2 | endometrioid adenocarcinoma | 52 | 1889 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1050 | ERA | I | 0 | serous borderline | 56 | 7.3 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | BBC |
| e1051 | ERA | IV | 1 | serous adenocarcinoma | 43 | 53 | BBC | BBC | BBC | BBC | CA | CA | CA | CA | CA | CA | CA | CA |
| e1052 | ERA | I | 3 | endometrioid adenocarcinoma | 56 | 157.3 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1053 | ERA | \* | \* | atypical leiomyoma | 44 | 114.2 | CA | BBC | CA | CA | BBC | CA | BBC | BBC | BBC | BBC | BBC | CA |
| e1054 | ERA | \* | \* | mucinous cystadenoma | 63 | 26 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| e1055 | ERA | \* | \* | serous cystadenofibroma | 61 | 381 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | CA |
| e1056 | ERA | I | 1 | mucinous adenocarcinoma | 50 | 228 | BBC | BBC | CA | CA | BBC | CA | CA | CA | BBC | CA | BBC | CA |
| e1057 | ERA | III | 3 | metastatic endometrioid endometrial adenocarcinoma | 58 | 257 | BBC | BBC | BBC | CA | CA | CA | CA | CA | CA | CA | BBC | CA |
| e1058 | ERA | \* | \* | benign Brenner tumor | 63 | 23 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| e1059 | ERA | I | 1 | adult Granulosa Cell tumor | 50 | 15.3 | BBC | BBC | CA | BBC | BBC | CA | CA | BBC | BBC | CA | BBC | BBC |
| e1060 | ERA | \* | \* | fibroma | 60 | 27 | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC | BBC |
| e1061 | ERA | IV | 3 | serous adenocarcinoma | 52 | 536 | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA | CA |
| e1062 | ERA | \* | \* | serous cystadenoma | 77 | 99 | BBC | BBC | BBC | BBC | BBC | BBC | CA | BBC | BBC | BBC | BBC | CA |
| e1063 | ERA | \* | \* | leiomyoma | 43 | 228 | CA | CA | CA | CA | BBC | BBC | BBC | CA | BBC | CA | CA | CA |
| PMP – Pelvic Mass Protocol  NECC – New England Case Control Study  ERA – Effects of Regional Analgesia on Serum miRNA after Oncology Surgery Study  \* - Not applicable; ‡ Not available  LDA - Linear discriminant analysis  LR - Logistic regression  NN – Neural network  SVM - Support vector machine  Bayes – Naive Bayes  MARS - Multivariate adaptive regression splines  FT – Functional tree  Bayes net - Bayesian network  RF – Random forest  EN – Elastic network regression  CA-125>35 – Serum CA-125 level greater than 35 unit/ml  BBC – Benign, Borderline, or Control  CA - Cancer | | | | | | | | | | | | | | | | | | |